Welcome to our dedicated page for Beyondspring SEC filings (Ticker: BYSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BeyondSpring Inc. (NASDAQ: BYSI) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a clinical-stage biopharmaceutical company. This SEC filings page aggregates those disclosures and, with AI-powered summaries, helps investors interpret the information most relevant to BeyondSpring’s oncology pipeline and capital structure.
Core filings include the annual report on Form 10‑K, which contains audited consolidated financial statements, notes on research and development spending, general and administrative expenses, net loss from continuing operations, and the presentation of SEED Therapeutics as discontinued operations. Current reports on Form 8‑K document material events such as quarterly financial results, equity offerings under an effective shelf registration statement, updates on the sale of BeyondSpring’s Series A‑1 preferred shares in SEED Therapeutics, and scheduling of the annual meeting of shareholders.
Investors can also review proxy materials, such as the definitive proxy statement on Schedule 14A, which outlines matters submitted to shareholder vote, including ratification of the independent registered public accounting firm. Additional 8‑K filings describe share purchase agreements, lock-up provisions for investors in registered offerings, and changes in BeyondSpring’s ownership percentage in SEED following new financing rounds.
Stock Titan’s AI tools assist by highlighting key elements in lengthy filings: trends in research and development and general and administrative expenses, cash and cash equivalents, deferred revenue, shareholders’ deficit, and noncontrolling interests. The platform also flags items related to capital raises, registration statements, and governance events. Real-time integration with EDGAR means new 10‑K, 8‑K, S‑3, and proxy filings for BYSI appear quickly, while AI-generated overviews help readers understand how each document fits into BeyondSpring’s broader clinical and financing strategy.
Decheng Capital entities disclosed multiple small sales of BeyondSpring Inc. (BYSI) ordinary shares in late September 2025. Fund III sold 1,800 shares on 09/25/2025 through 09/29/2025 in three reported transactions (700 at a weighted average $1.66, 600 at $1.68, 500 at $1.75), reducing Fund III's reported holdings to 1,845,761 shares after the last sale. Related Decheng entities report additional indirect holdings of 1,617,409 shares (Fund II) and 891,734 shares (Global Healthcare Master).
The filings identify Decheng Capital Management III (GP III) and Dr. Xiangmin (Cui) as manager/related parties and state that GP and Dr. Cui may be deemed beneficial owners of the funds' holdings but disclaim direct ownership except for pecuniary interest. The transactions are reported as sales with weighted average price ranges disclosed in footnotes.
Decheng Capital-related funds and manager Dr. Xiangmin Cui reported insider sales of BeyondSpring Inc. (BYSI) ordinary shares over three consecutive days in September 2025. The filings show Fund III sold 5,410 shares on 09/22/2025 at a weighted average price of $1.83, 4,106 shares on 09/23/2025 at $1.72, and 2,256 shares on 09/24/2025 at $1.68, for a total of 11,772 shares sold across the three transactions. After these sales, Fund III beneficially owned 1,847,561 shares. The Form 4 also discloses indirect holdings by affiliated vehicles: Fund II holds 1,617,409 shares and Decheng Capital Global Healthcare Fund (Master) holds 891,734 shares. The filings state the reported prices are weighted averages for multiple transactions within specified ranges and identify Decheng Capital management entities and Dr. Cui as the reporting persons.
BeyondSpring Inc. reports that its majority-owned indirect subsidiary SEED Therapeutics Inc. has completed a second closing of its Series A-3 financing. On September 22, 2025, SEED entered into share purchase agreements with third-party investors to sell an aggregate of 1,411,761 Series A-3 Preferred Shares for an aggregate cash purchase price of $6 million, at $4.25 per share.
This follows SEED’s August 2024 sale of 5,647,059 Series A-3 Preferred Shares for $24 million at the same price per share. After the second close, BeyondSpring and its subsidiary SEED Technology Limited are expected to own approximately 38.03% of SEED’s outstanding equity on an as-converted basis, excluding any employee equity plans. BeyondSpring expects that SEED will continue to be consolidated into its financial statements because BeyondSpring believes it remains in substantive control of SEED.
Decheng Capital entities reported insider dispositions of BeyondSpring Inc. (BYSI) ordinary shares across three days in September 2025. Decheng Capital China Life Sciences USD Fund III sold 2,304 shares on 09/17/2025 at a weighted average price of $1.83, 5,307 shares on 09/18/2025 at $1.74, and 3,656 shares on 09/19/2025 at $1.79, totaling 11,267 shares sold and leaving Fund III with 1,859,333 shares. The filing also shows indirect holdings of 1,617,409 shares by Decheng Capital China Life Sciences USD Fund II and 891,734 shares by Decheng Capital Global Healthcare Fund (Master), LP. Footnotes explain weighted average pricing ranges and that GP entities and Dr. Xiangmin Cui may be deemed beneficial owners but disclaim direct ownership except for pecuniary interest.
Insider sales by Decheng-affiliated funds in BeyondSpring (BYSI) The filing shows Decheng Capital entities and Dr. Xiangmin Cui reported a series of open-market dispositions of BeyondSpring ordinary shares in mid-September 2025. Decheng Capital China Life Sciences USD Fund III, L.P. sold a total of 4,110 shares across trades on 09/12/2025, 09/15/2025 and 09/16/2025 at weighted-average prices reported as $1.85, $1.84 and $1.88 respectively. After those sales, Fund III’s reported beneficial ownership was 1,870,600 shares. The filing also reports indirect beneficial ownership of 1,617,409 shares by Decheng Capital China Life Sciences USD Fund II, L.P. and 891,734 shares by Decheng Capital Global Healthcare Fund (Master), LP. Signatures indicate Dr. Xiangmin Cui as manager executing the filing on behalf of the Decheng entities on 09/16/2025.
BeyondSpring Inc. held its 2025 annual meeting of shareholders on September 15, 2025. Shareholders representing 21,852,265 ordinary shares, or approximately 54.19% of the 40,322,320 outstanding shares entitled to vote as of the July 25, 2025 record date, were present or represented by proxy. Shareholders ratified the appointment of CBIZ CPAs P.C. as the companys independent registered public accounting firm for the fiscal year ending December 31, 2025, with 21,831,390 votes in favor, 14,265 against, and 6,610 abstentions.
Decheng Capital affiliates and Dr. Xiangmin Cui reported sales of BeyondSpring Inc. (BYSI) ordinary shares across three days in September 2025. The filings show Fund III sold 9,050 shares on 09/09/2025 at a weighted average price of $1.97, 8,176 shares on 09/10/2025 at $1.93, and 3,820 shares on 09/11/2025 at $1.90 (weighted averages covering ranges $1.90–$2.00 and $1.87–$1.94). After these transactions Fund III beneficially owned 1,874,710 shares. Related Decheng entities report additional indirect holdings: Fund II 1,617,409 shares and Global Healthcare Fund 891,734 shares. The Form 4s identify Decheng Capital Management entities and Dr. Cui as reporting persons and include standard disclosure footnotes about beneficial ownership and weighted average pricing.
Decheng Capital-related entities reported sales of BeyondSpring Inc. (BYSI) ordinary shares. Decheng Capital China Life Sciences USD Fund III, L.P. sold 803 shares on 09/04/2025 at a weighted-average price of $1.82, 1,106 shares on 09/05/2025 at $1.86, and 7,090 shares on 09/08/2025 at $1.93, leaving Fund III with 1,895,756 shares beneficially owned. The filing also reports indirect holdings of 1,617,409 shares by Decheng Capital China Life Sciences USD Fund II, L.P. and 891,734 shares by Decheng Capital Global Healthcare Fund (Master), LP. Footnotes state the reported prices are weighted averages across specified price ranges and that the general partners and Dr. Xiangmin (Cui) may be deemed to beneficially own the funds' holdings. The Form 4 is signed by Xiangmin Cui on 09/08/2025.
Decheng Capital-affiliated funds and Dr. Xiangmin Cui reported sales of BeyondSpring Inc. (BYSI) ordinary shares in late August and early September 2025. The filing shows Decheng Capital China Life Sciences USD Fund III, L.P. sold 800 shares on 08/29/2025, 2,800 shares on 09/02/2025 and 1,270 shares on 09/03/2025 at weighted-average prices in the $1.67–$1.84 range, reducing Fund III’s reported beneficial ownership to 1,904,755 shares.
Other related entities retain beneficial holdings: Decheng Capital China Life Sciences USD Fund II, L.P. holds 1,617,409 shares and Decheng Capital Global Healthcare Fund (Master), LP holds 891,734 shares. Footnotes explain the holdings are held directly by the named funds, GP entities and Dr. Cui may be deemed to beneficially own such securities, and the reported prices are weighted averages across multiple transactions.
Decheng Capital entities reported multiple small open-market sales of BeyondSpring Inc. (BYSI) ordinary shares between August 26 and August 28, 2025. Fund III sold 2,000 shares on 08/26/2025 at a weighted-average price of $1.79, 1,300 shares on 08/27/2025 at $1.78, and 809 shares on 08/28/2025 at $1.81; those disposals reduced Fund III's beneficial holding to 1,909,625 shares. The filing discloses additional indirect holdings: Fund II holds 1,617,409 shares and Decheng Global Healthcare (Master) LP holds 891,734 shares. The reporting chain shows common control through Decheng Capital management entities and Dr. Xiangmin (Xiangmin) Cui as manager, with standard disclaimers of beneficial ownership by general partners except for pecuniary interest. Footnotes state the prices are weighted averages across multiple transactions within disclosed price ranges.
FAQ
What is the current stock price of Beyondspring (BYSI)?
What is the market cap of Beyondspring (BYSI)?
